New stem cell filter could reduce transplant rejection

NCT ID NCT03626285

Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study offers a special stem cell transplant to people with cancer or other disorders who lack a perfectly matched donor. Doctors use a device to purify stem cells from a partially matched donor, removing immune cells that can cause rejection or attack the patient's body. The goal is to make the transplant safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: CD34-selected peripheral blood stem cells
What this could lead to: If successful, this approach could make stem cell transplants safer and more available for patients who lack a perfectly matched donor.
What could go wrong: This is an early access protocol, not a controlled trial, so results are uncertain. Risks include graft failure, infection, and graft-versus-host disease despite the CD34 selection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with malignant or nonmalignant diseases that can benefit from alternative stem cell transplantation according to institutional standard practice guidelines * Patients lacking a healthy human leukocyte antigen (HLA)-identical related donor and having one of the following alternative donor sources: * HLA-haploidentical related (HLA antigen genotypic match \>= 4/8 and \<= 7/8) or * Unrelated donor that is HLA matched at \>= 7/8 HLA antigen loci * The selected donor must also be: * Able to receive granulocyte colony-stimulating factor (G-CSF, filgrastim) and undergo apheresis either through placement of peripheral or temporary central venous catheter, based on institutional guidelines for peripheral blood stem cell collection * Meet all institutional standard criteria for clearance for peripheral stem cell collection * Recipients must meet institutional treatment standards based on pre-transplant evaluations including: * Adequate major organ functions * Free of major systemic infections * Not pregnant, if female of childbearing age (post-pubertal) * Recipient (if \>= 18 years) or their parent/legal guardian (if \< 18 years) must be able to sign the informed consent form for the treatment plan; assent will be obtained from recipients 7-17 years of age, in accordance to our institutional guidelines Exclusion Criteria: * Patients not meeting clearance criteria for bone marrow transplantation (BMT) based on standard institutional guidelines * Presence of anti-HLA antibodies against donor antigens in a recipient or anti-HLA antibodies against recipient antigens in a donor * Known allergy to murine (mouse) protein or iron-dextran

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign neoplasm cancer disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign neoplasm Bone marrow transplantation recipient Hematopoietic cell transplantation recipient Malignant neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New stem cell filter could reduce transplant rejection

What the study statuses mean